No takes yet. Share an insight, caveat, or question.
This analysis compares drug levels between subcutaneous and intravenous infliximab in IBD, indicating potential for better treatment outcomes.
Roblin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: